Your browser doesn't support javascript.
loading
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells.
Lee, Sooncheol; Micalizzi, Douglas; Truesdell, Samuel S; Bukhari, Syed I A; Boukhali, Myriam; Lombardi-Story, Jennifer; Kato, Yasutaka; Choo, Min-Kyung; Dey-Guha, Ipsita; Ji, Fei; Nicholson, Benjamin T; Myers, David T; Lee, Dongjun; Mazzola, Maria A; Raheja, Radhika; Langenbucher, Adam; Haradhvala, Nicholas J; Lawrence, Michael S; Gandhi, Roopali; Tiedje, Christopher; Diaz-Muñoz, Manuel D; Sweetser, David A; Sadreyev, Ruslan; Sykes, David; Haas, Wilhelm; Haber, Daniel A; Maheswaran, Shyamala; Vasudevan, Shobha.
Affiliation
  • Lee S; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Micalizzi D; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Truesdell SS; Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Bukhari SIA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, 02138, USA.
  • Boukhali M; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Lombardi-Story J; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Kato Y; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Choo MK; Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Dey-Guha I; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, 02138, USA.
  • Ji F; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Nicholson BT; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Myers DT; Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Lee D; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, 02138, USA.
  • Mazzola MA; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Raheja R; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Langenbucher A; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Haradhvala NJ; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Lawrence MS; Laboratory of Oncology, Hokuto Hospital, Obihiro, Japan.
  • Gandhi R; Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.
  • Tiedje C; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Diaz-Muñoz MD; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, Massachusetts, USA.
  • Sweetser DA; Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Sadreyev R; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Sykes D; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
  • Haas W; Department of Convergence Medical Science, Pusan National University School of Medicine, Yangsan, 50612, 1257-1258, South Korea.
  • Haber DA; Center for Neurological Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Maheswaran S; Center for Neurological Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Vasudevan S; Massachusetts General Hospital Cancer Center, Harvard Medical School, 185 Cambridge St, CPZN4202, Boston, MA, 02114, USA.
Genome Biol ; 21(1): 33, 2020 02 10.
Article in En | MEDLINE | ID: mdl-32039742
ABSTRACT

BACKGROUND:

Quiescence (G0) is a transient, cell cycle-arrested state. By entering G0, cancer cells survive unfavorable conditions such as chemotherapy and cause relapse. While G0 cells have been studied at the transcriptome level, how post-transcriptional regulation contributes to their chemoresistance remains unknown.

RESULTS:

We induce chemoresistant and G0 leukemic cells by serum starvation or chemotherapy treatment. To study post-transcriptional regulation in G0 leukemic cells, we systematically analyzed their transcriptome, translatome, and proteome. We find that our resistant G0 cells recapitulate gene expression profiles of in vivo chemoresistant leukemic and G0 models. In G0 cells, canonical translation initiation is inhibited; yet we find that inflammatory genes are highly translated, indicating alternative post-transcriptional regulation. Importantly, AU-rich elements (AREs) are significantly enriched in the upregulated G0 translatome and transcriptome. Mechanistically, we find the stress-responsive p38 MAPK-MK2 signaling pathway stabilizes ARE mRNAs by phosphorylation and inactivation of mRNA decay factor, Tristetraprolin (TTP) in G0. This permits expression of ARE mRNAs that promote chemoresistance. Conversely, inhibition of TTP phosphorylation by p38 MAPK inhibitors and non-phosphorylatable TTP mutant decreases ARE-bearing TNFα and DUSP1 mRNAs and sensitizes leukemic cells to chemotherapy. Furthermore, co-inhibiting p38 MAPK and TNFα prior to or along with chemotherapy substantially reduces chemoresistance in primary leukemic cells ex vivo and in vivo.

CONCLUSIONS:

These studies uncover post-transcriptional regulation underlying chemoresistance in leukemia. Our data reveal the p38 MAPK-MK2-TTP axis as a key regulator of expression of ARE-bearing mRNAs that promote chemoresistance. By disrupting this pathway, we develop an effective combination therapy against chemosurvival.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Processing, Post-Transcriptional / Drug Resistance, Neoplasm / Tristetraprolin / AU Rich Elements Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Genome Biol Journal subject: BIOLOGIA MOLECULAR / GENETICA Year: 2020 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA Processing, Post-Transcriptional / Drug Resistance, Neoplasm / Tristetraprolin / AU Rich Elements Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Genome Biol Journal subject: BIOLOGIA MOLECULAR / GENETICA Year: 2020 Document type: Article Affiliation country: United States